Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, Multicenter, 18 Week Pilot Study to Investigate the Neuroprotective Effect of PROCRIT (Epoetin Alfa) on the Development of Peripheral Neuropathy in Patients Receiving Combination Taxane and Platinum-Based Chemotherapy for Cancer
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 14 Jul 2014
Price :
$35
*
At a glance
- Drugs Epoetin alfa (Primary) ; Epoetin alfa (Primary)
- Indications Peripheral neuropathies
- Focus Therapeutic Use
- Sponsors Janssen Research & Development
- 16 May 2014 New trial record
- 13 Apr 2009
- 16 Oct 2008